Each of these has a name, a cause, and a treatment pathway. Being common does not make any of them something you have to live with.
Reduced interest in sex that causes you distress. When it is persistent and distressing, it has a clinical name and specific treatments — including two FDA-approved medications.
Dyspareunia is never something to push through. It has identifiable causes — tissue changes, pelvic floor tension, vulvar pain conditions, endometriosis — and pushing through makes several of them worse.
The genitourinary syndrome of menopause affects a large proportion of women after menopause and, unlike hot flashes, it worsens over time without treatment rather than resolving.
Difficulty becoming aroused or reaching orgasm, whether lifelong or newly changed. Frequently medication-related, and frequently reversible once identified.
Before treating low desire as a disorder, it is worth understanding how desire actually works — because a great many women are distressed by something that is entirely normal.
Desire appears seemingly out of nowhere — a thought, an urge, wanting sex before anything has happened. This is the model almost every film and advertisement depicts, and it is more commonly reported by men and by people earlier in a relationship.
Desire emerges in response to context, touch, and arousal rather than preceding them. You may not feel like sex beforehand, yet become genuinely interested once things are underway. This is extremely common in women, particularly in long-term relationships.
The clinical threshold is distress. If you have responsive rather than spontaneous desire and that works fine for you, nothing needs treating — you are not broken, and you do not have a disorder. Many women arrive believing something is wrong simply because their experience does not match a cultural script.
Where desire has genuinely dropped from your own baseline, and that loss bothers you — not only a partner — that is worth investigating. There is usually a reason: a hormonal shift, a medication, pain that has made sex something to brace against, exhaustion, or a relationship dynamic. We look for the reason rather than starting from the assumption that your desire is defective.
Female sexual response involves hormones, blood flow, nerves, pelvic floor muscles, mood, medication, and context. Most women have more than one factor at play.
Perimenopause, menopause, postpartum, and breastfeeding all shift oestrogen and testosterone. Falling oestrogen thins and dries genital tissue; falling testosterone can reduce desire.
SSRIs and SNRIs are among the most common causes of reduced desire, arousal, and orgasm difficulty. Hormonal contraception, some blood pressure medications, and antihistamines also contribute.
Overly tight or uncoordinated pelvic floor muscles are a frequently missed cause of painful sex, particularly after childbirth or a period of pain that led to guarding.
Depression, anxiety, chronic stress, and exhaustion suppress desire directly — and the medications used to treat them often compound it. Sleep debt alone is a substantial factor.
Desire does not exist in isolation from the relationship it sits in. Unresolved conflict, mismatched expectations, and a partner’s own sexual difficulty all matter clinically.
Endometriosis, thyroid disease, diabetes, autoimmune conditions such as lichen sclerosus, chronic pain, and cancer treatment all affect sexual function and are worth excluding.
Being told to “relax”, use more lubricant, or have a glass of wine is not treatment. Pain during sex has specific causes, and identifying which one you have determines everything about what helps.
Treatment follows the cause. Where the tissue is the problem, we treat the tissue; where the muscles are, physical therapy does the work medication cannot.
One point worth emphasising: continuing to have painful sex tends to make the problem worse, because the pelvic floor learns to brace in anticipation. Early assessment genuinely changes the trajectory.
Two medications are FDA-approved specifically for distressing low desire in premenopausal women. Beyond those, the options depend on your stage of life and what is driving the change.
Taken every night, it acts on brain neurotransmitter systems rather than on blood flow. It is not taken before sex and takes several weeks to show an effect. Blood pressure drops and fainting are the notable risks, and alcohol requires specific caution.
A small self-administered injection used ahead of anticipated sexual activity rather than daily. Acts on melanocortin receptors in the brain. Nausea is the most common side effect and is not rare.
International consensus supports testosterone for distressing low desire in postmenopausal women — the one indication with reasonable evidence. There is no FDA-approved female formulation in the US, so it is prescribed off-label at a fraction of a male dose with monitoring.
The interventions with the strongest evidence for low desire are not always pharmaceutical. Cognitive behavioural therapy and mindfulness-based approaches have solid evidence, as does psychosexual therapy where relationship context is a factor. Reviewing an antidepressant that may be contributing, treating pain that has made sex something to dread, and addressing sleep and stress often achieve more than any tablet. We will tell you when that is the case, even though it is the less profitable answer.
These are marketed heavily and priced accordingly. Here is what regulators and professional societies actually say.
Fractional CO2 and Er:YAG lasers and radiofrequency devices are widely marketed for “vaginal rejuvenation”, dryness, and painful sex. The FDA issued a safety communication warning about this marketing and stating it has not approved these devices for any specific gynaecological indication. A 2022 urogynaecology consensus concluded these lasers have yet to show promise for vulvovaginal atrophy, dryness, or menopausal painful sex, and that long-term effects remain unknown.
PRP injection into genital tissue is promoted for desire, arousal, and orgasm. The evidence consists largely of small uncontrolled studies without the blinded, placebo-controlled trials needed to separate a real effect from expectation — which matters enormously in sexual medicine, where placebo response is substantial. It is not an FDA-approved treatment for sexual dysfunction.
These are among the most expensive things a wellness clinic can sell, and they are routinely offered to women who have never been assessed for the causes described further up this page. Before considering either, it is worth knowing whether low oestrogen, a pelvic floor that has learned to brace, or an antidepressant is the actual problem — because those have established treatments that cost a fraction as much and are far more likely to work.
An hour, not ten minutes. What has changed, when it started, what it feels like, what you have already tried, and what you actually want to be different.
Hormones, thyroid, iron, and glucose where relevant, a full medication review, and — where pain is the concern — an appropriate examination or referral.
Your provider talks you through what is likely driving it and what each option realistically offers, including where the honest answer is therapy or physical therapy rather than a prescription.
Start with the option most likely to address your specific cause, then review. Most women need one or two adjustments, and some need a combined approach.
A consultation long enough to cover this properly, and treatment priced monthly with medication and follow-up included.
A full hour with a provider, plus the labs and medication review that identify what is actually driving it.
Ongoing physician-managed treatment with medication and adjustments included.
Sexual health integrated with menopause and hormone care in one plan.
We do not sell vaginal laser packages or PRP injections. If the evidence-supported options are not the right fit, we refer you to gynaecology or pelvic floor physical therapy rather than escalate to something unproven.
Women are routinely told that painful sex is normal, or that low desire is something to accept. It is neither. Your symptoms are treated as clinical information, not as something to manage your expectations about.
Including when the honest answer is pelvic floor physical therapy or a medication review rather than something we could sell you. And including where popular treatments are not supported at all.
A full hour for the first appointment, discreet delivery, and a provider who has had this conversation many times. Nothing you raise will be the first time they have heard it.
Desire changes across a lifetime, and the shift from spontaneous desire to responsive desire — where interest arrives after arousal begins rather than before — is extremely common, particularly in long-term relationships. That is a normal variation, not a disorder. The clinical question is whether the change distresses you. If it does, there is usually an identifiable reason worth investigating: a hormonal shift, a medication, pain, exhaustion, or relationship context.
Painful sex is always worth assessing, and it is never something to push through — continuing tends to worsen it, because the pelvic floor learns to brace in anticipation. Common causes include the tissue changes of menopause, pelvic floor muscles held too tight, vulvar pain conditions, vaginismus, endometriosis, and skin conditions such as lichen sclerosus. Treatment follows the cause: local oestrogen or vaginal DHEA for tissue-related pain, pelvic floor physical therapy for muscular causes, and referral where a specialist is needed.
Very possibly. SSRIs and SNRIs are among the most common causes of reduced desire, difficulty with arousal, and difficulty reaching orgasm, and the effect is frequently not discussed when the medication is started. This does not mean stopping your antidepressant — that decision belongs with the prescriber managing your mental health. But there are options: dose adjustment, switching to an agent with a lower rate of sexual side effects, or adding a strategy specifically for this. It is worth raising.
Not in the way the phrase suggests. PDE5 inhibitors work on blood flow, and low desire in women is generally not a blood flow problem. Two medications are FDA-approved specifically for distressing low desire in premenopausal women: flibanserin, taken nightly and acting on brain neurotransmitters over several weeks, and bremelanotide, a self-administered injection used before anticipated activity. Both have real side effects and neither is a simple equivalent. For postmenopausal women, low-dose testosterone has the better evidence base.
